NeuroPace (NPCE) Preferred Stock Liabilities (2020 - 2021)
NeuroPace has reported Preferred Stock Liabilities over the past 2 years, most recently at $141.4 million for Q1 2021.
- For Q1 2021, Preferred Stock Liabilities rose 92.23% year-over-year to $141.4 million; the TTM value through Mar 2021 reached $141.4 million, up 92.23%, while the annual FY2020 figure was $141.4 million, N/A changed from the prior year.
- Preferred Stock Liabilities for Q1 2021 was $141.4 million at NeuroPace, roughly flat from $141.4 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $141.4 million in Q3 2020 and troughed at $73.5 million in Q2 2020.